Triumvira Immunologics and Lonza Announce Collaboration to Develop Innovative Point-of-Care Manufacturing for TAC T-Cell Therapeutic Targeting Solid Tumors

March 24, 2020

AUSTIN, Texas & HAMILTON, Ontario & BASEL, Switzerland–(BUSINESS WIRE)–Triumvira Immunologics Inc. (Triumvira), a private, clinical-stage biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, and Lonza, a leading cell & gene therapy manufacturer, announced today that the companies have an agreement in place.

This collaboration, aimed at the development of Triumvira’s TAC01-HER2 T-cell therapy for treating solid tumors, will leverage Lonza’s expertise in process development and the usage of its proprietary Cocoon® Platform. This automated patient-scale cell therapy manufacturing platform offers flexibility to execute a wide variety of protocols within a single system that is enabled through a single-use, highly customizable cassette, and custom programming.

Immunotherapy, particularly T-cell products, belong to the most potent drugs that could overcome the complex barriers encountered in solid tumors. However, current T-cell approaches remain insufficiently effective. The TAC receptor represents a significant advancement, providing a novel mechanism of T-cell activation, leading to improved anti-tumor responses in solid tumor models.